EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007

Caroline Burgard, Madita Frei, Arne Blickle, Philipp E Hartrampf, Manuela A Hoffmann, Mathias Schreckenberger, Hans-Peter Schmid, Lena Unterrainer, Julian Rogasch, Markus Galler, Samer Ezziddin, Florian Rosar iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07292-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Caroline Burgard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Prostate-Specific Antigen, Oligopeptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität des Saarlandes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels, data on the efficacy of PSMA PET/CT at very low PSA values (≤ 0.2 ng/mL) remain limited.

Methods

In this multicenter study, we analyzed 321 patients with BCR and a PSA value ≤ 0.2 ng/mL across five German academic centers, using three different PSMA-targeted radiotracers: [ 68 Ga]Ga-PSMA-11, [ 68 Ga]Ga-PSMA I&T, and [ 18 F]PSMA-1007 and analyzed the detection rates and potential predictive parameters.

Results

The overall pooled detection rate was 29.6%. No statistically significant differences in detection rates were observed between the three radiotracers ([ 68 Ga]Ga-PSMA-11 29.4% vs. [ 68 Ga]Ga-PSMA I&T, 22.5% vs. [ 18 F]PSMA-1007 32.4%, p ≥ 0.314). Detection rates were significantly higher in patients with a PSA level > 0.15 ng/mL ( p = 0.029, φ = 0.122), in those with an initial Gleason score > 7 ( p = 0.018, φ = 0.141) and in those receiving androgen deprivation therapy ( p = 0.031, φ = 0.120).

Conclusion

All three radiotracers demonstrated comparable diagnostic performance, with no significant superiority observed between the 68 Ga- and 18 F-labeled tracers in the patient sample investigated (overall pooled detection rate: 29.6%). This positivity rate can serve as an expectation horizon for both the attending physician and the patient in the case of low PSA values. Further studies with larger cohorts, preferably conducted in a prospective setting, are needed to confirm and expand upon our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsProstate-Specific AntigenOligopeptidesEdetic AcidAntigens, SurfaceGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingHumansMaleGallium RadioisotopesAgedMiddle AgedGallium IsotopesGermanyRecurrenceFluorine RadioisotopesRadioactive TracersAged, 80 and overRadiopharmaceuticalsNiacinamide

Stichwörter der Autor:innen

Biochemical recurrenceDetection ratePET/CTPSAPSMAPSMA I&TPSMA-1007PSMA-11

Substanzen

Gallium Radioisotopesgallium 68 PSMA-11Prostate-Specific AntigenPSMA-1007OligopeptidesGallium IsotopesEdetic AcidAntigens, SurfaceGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
  • Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Department of Nuclear Medicine, Johannes Gutenberg University- Medical Center, Mainz, Germany.
  • Department of Nuclear Medicine, Ludwig Maximilian University of Munich- University Hospital, Munich, Germany.
  • Bavarian Cancer Research Center (BZKF), Partner Site Munich, Munich, Germany.
  • Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

ORCID-Profile: Florian Rosar

Förderung

  • Universität des Saarlandes

Zitieren

APA

Burgard, C., Frei, M., Blickle, A., Hartrampf, P. E., Hoffmann, M. A., Schreckenberger, M., Schmid, H. P., Unterrainer, L., Rogasch, J., Galler, M., Ezziddin, S., & Rosar, F. (2025). PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07292-1

Vancouver

Burgard C, Frei M, Blickle A, Hartrampf PE, Hoffmann MA, Schreckenberger M, et al. PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07292-1

BibTeX
@article{Burgard2025,
  author = {Burgard, Caroline and Frei, Madita and Blickle, Arne and Hartrampf, Philipp E and Hoffmann, Manuela A and Schreckenberger, Mathias and Schmid, Hans-Peter and Unterrainer, Lena and Rogasch, Julian and Galler, Markus and Ezziddin, Samer and Rosar, Florian},
  title = {PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07292-1}
}
Kostenlos starten →